Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population

: The aim of this study was to evaluate age-related changes in free/total prostate-specific antigen (f/t PSA) ratio, focusing on the avoidance of unnecessary prostate biopsies. : A total of 898 men aged 30–88 years without a history of prostate surgery and disease were enrolled into the study. Serum...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical chemistry and laboratory medicine 2007-01, Vol.45 (7), p.912-916
Hauptverfasser: Mungan, A. Gorkem, Erol, Bulent, Akduman, Bulent, Bozdogan, Gurdal, Kiran, Sibel, Yesilli, Cetin, Mungan, N. Aydin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 916
container_issue 7
container_start_page 912
container_title Clinical chemistry and laboratory medicine
container_volume 45
creator Mungan, A. Gorkem
Erol, Bulent
Akduman, Bulent
Bozdogan, Gurdal
Kiran, Sibel
Yesilli, Cetin
Mungan, N. Aydin
description : The aim of this study was to evaluate age-related changes in free/total prostate-specific antigen (f/t PSA) ratio, focusing on the avoidance of unnecessary prostate biopsies. : A total of 898 men aged 30–88 years without a history of prostate surgery and disease were enrolled into the study. Serum tPSA, fPSA and f/t PSA ratios were determined for the study population and for different age categories. All males who had suspicious digital rectal examination and tPSA >4 ng/mL underwent transrectal ultrasonography-guided prostate biopsy. Receiver operating characteristic (ROC) curves for each group were generated by plotting the sensitivity vs. 1–specificity for the f/t PSA ratio. The sensitivity and specificity were obtained using different f/t PSA ratio cutoffs for different age groups. : Prostate cancer was detected in 63 patients (7%). Age-specific cutoffs were determined according to likelihood ratios at the levels of 10%, 15% and 15% f/t PSA ratio for ages 50–59, 60–69 and ≥70 years, respectively. However, a single cutoff of 10% is recommended across all age ranges (positive likelihood ratio 2.36). ROC curves demonstrated that the area under the curve (AUC) was significant for all patients with initial PSA of 4–10 ng/mL (AUC 0.703–0.796), except for the ≥70-year age group (AUC 0.549). : The current study showed that the use of f/t PSA ratio in patients with PSA levels of 4–10 ng/mL should enhance the specificity of PSA screening and decrease the number of unnecessary biopsies. f/t PSA levels may show dissimilarities according to age and ethnicity, so further studies are warranted to identify this relationship. Clin Chem Lab Med 2007;45:912–6.
doi_str_mv 10.1515/CCLM.2007.501
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70709773</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70709773</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-1f4976e8f944b515ada1b8640dca92eb0a68159efd6fd521c668b6e699c4a3ee3</originalsourceid><addsrcrecordid>eNptkD2P1DAQhiME4j6gpEVuoMueHX8lUJ1WHCAtojloo4kzXnx4nWA7oP0B_G-8H9I1VB6PnhnN-1TVK0ZXTDJ5s15vvqwaSvVKUvakumSC61pwzp4ea1Er1bCL6iqlB0qZlEI_ry6YVkxTri-rv9_BL5iInSKxEfEmTxk8meOUMmSs04zGWWcIhOy2GEiE7CYCiQCxSzDlE8hkCWzxHQloMCWX94dORIsRg0HyG7wb4Ui6UObul_jTpR9knubFH_svqmcWfMKX5_e6-nb34X79qd58_fh5fbupDdc818yKTitsbSfEUMLDCGxolaCjga7BgYJqmezQjsqOsmFGqXZQqLrOCOCI_Lp6e9pb8v0qsXO_c8mg9xBwWlKvqaad1ryA9Qk0RUQqUfo5uh3Efc9of_DeH7z3B-998V741-fFy7DD8ZE-iy7AmzMAyYC3EYJx6ZFrOyk1FYV7f-L-gM8YR9zGZV-K_mFaYihu_n-AkLpjDf8HIKKgMQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70709773</pqid></control><display><type>article</type><title>Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population</title><source>MEDLINE</source><source>De Gruyter journals</source><creator>Mungan, A. Gorkem ; Erol, Bulent ; Akduman, Bulent ; Bozdogan, Gurdal ; Kiran, Sibel ; Yesilli, Cetin ; Mungan, N. Aydin</creator><creatorcontrib>Mungan, A. Gorkem ; Erol, Bulent ; Akduman, Bulent ; Bozdogan, Gurdal ; Kiran, Sibel ; Yesilli, Cetin ; Mungan, N. Aydin</creatorcontrib><description>: The aim of this study was to evaluate age-related changes in free/total prostate-specific antigen (f/t PSA) ratio, focusing on the avoidance of unnecessary prostate biopsies. : A total of 898 men aged 30–88 years without a history of prostate surgery and disease were enrolled into the study. Serum tPSA, fPSA and f/t PSA ratios were determined for the study population and for different age categories. All males who had suspicious digital rectal examination and tPSA &gt;4 ng/mL underwent transrectal ultrasonography-guided prostate biopsy. Receiver operating characteristic (ROC) curves for each group were generated by plotting the sensitivity vs. 1–specificity for the f/t PSA ratio. The sensitivity and specificity were obtained using different f/t PSA ratio cutoffs for different age groups. : Prostate cancer was detected in 63 patients (7%). Age-specific cutoffs were determined according to likelihood ratios at the levels of 10%, 15% and 15% f/t PSA ratio for ages 50–59, 60–69 and ≥70 years, respectively. However, a single cutoff of 10% is recommended across all age ranges (positive likelihood ratio 2.36). ROC curves demonstrated that the area under the curve (AUC) was significant for all patients with initial PSA of 4–10 ng/mL (AUC 0.703–0.796), except for the ≥70-year age group (AUC 0.549). : The current study showed that the use of f/t PSA ratio in patients with PSA levels of 4–10 ng/mL should enhance the specificity of PSA screening and decrease the number of unnecessary biopsies. f/t PSA levels may show dissimilarities according to age and ethnicity, so further studies are warranted to identify this relationship. Clin Chem Lab Med 2007;45:912–6.</description><identifier>ISSN: 1434-6621</identifier><identifier>EISSN: 1437-4331</identifier><identifier>DOI: 10.1515/CCLM.2007.501</identifier><identifier>PMID: 17617037</identifier><language>eng</language><publisher>Berlin: Walter de Gruyter</publisher><subject>Adult ; age ; Aged ; Aged, 80 and over ; Aging - blood ; Biological and medical sciences ; General aspects ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical sciences ; Middle Aged ; prostate cancer ; prostate-specific antigen ; Prostate-Specific Antigen - blood ; Prostatic Hyperplasia - diagnosis ; Prostatic Hyperplasia - physiopathology ; Prostatic Neoplasms - diagnosis ; reference validation ; Reference Values ; ROC Curve ; Sensitivity and Specificity ; Turkey</subject><ispartof>Clinical chemistry and laboratory medicine, 2007-01, Vol.45 (7), p.912-916</ispartof><rights>2007 by Walter de Gruyter Berlin New York</rights><rights>2007 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-1f4976e8f944b515ada1b8640dca92eb0a68159efd6fd521c668b6e699c4a3ee3</citedby><cites>FETCH-LOGICAL-c373t-1f4976e8f944b515ada1b8640dca92eb0a68159efd6fd521c668b6e699c4a3ee3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.degruyter.com/document/doi/10.1515/CCLM.2007.501/pdf$$EPDF$$P50$$Gwalterdegruyter$$H</linktopdf><linktohtml>$$Uhttps://www.degruyter.com/document/doi/10.1515/CCLM.2007.501/html$$EHTML$$P50$$Gwalterdegruyter$$H</linktohtml><link.rule.ids>314,776,780,27903,27904,66501,68285</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=18955704$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17617037$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Mungan, A. Gorkem</creatorcontrib><creatorcontrib>Erol, Bulent</creatorcontrib><creatorcontrib>Akduman, Bulent</creatorcontrib><creatorcontrib>Bozdogan, Gurdal</creatorcontrib><creatorcontrib>Kiran, Sibel</creatorcontrib><creatorcontrib>Yesilli, Cetin</creatorcontrib><creatorcontrib>Mungan, N. Aydin</creatorcontrib><title>Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population</title><title>Clinical chemistry and laboratory medicine</title><addtitle>Clin Chem Lab Med</addtitle><description>: The aim of this study was to evaluate age-related changes in free/total prostate-specific antigen (f/t PSA) ratio, focusing on the avoidance of unnecessary prostate biopsies. : A total of 898 men aged 30–88 years without a history of prostate surgery and disease were enrolled into the study. Serum tPSA, fPSA and f/t PSA ratios were determined for the study population and for different age categories. All males who had suspicious digital rectal examination and tPSA &gt;4 ng/mL underwent transrectal ultrasonography-guided prostate biopsy. Receiver operating characteristic (ROC) curves for each group were generated by plotting the sensitivity vs. 1–specificity for the f/t PSA ratio. The sensitivity and specificity were obtained using different f/t PSA ratio cutoffs for different age groups. : Prostate cancer was detected in 63 patients (7%). Age-specific cutoffs were determined according to likelihood ratios at the levels of 10%, 15% and 15% f/t PSA ratio for ages 50–59, 60–69 and ≥70 years, respectively. However, a single cutoff of 10% is recommended across all age ranges (positive likelihood ratio 2.36). ROC curves demonstrated that the area under the curve (AUC) was significant for all patients with initial PSA of 4–10 ng/mL (AUC 0.703–0.796), except for the ≥70-year age group (AUC 0.549). : The current study showed that the use of f/t PSA ratio in patients with PSA levels of 4–10 ng/mL should enhance the specificity of PSA screening and decrease the number of unnecessary biopsies. f/t PSA levels may show dissimilarities according to age and ethnicity, so further studies are warranted to identify this relationship. Clin Chem Lab Med 2007;45:912–6.</description><subject>Adult</subject><subject>age</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Aging - blood</subject><subject>Biological and medical sciences</subject><subject>General aspects</subject><subject>Humans</subject><subject>Investigative techniques, diagnostic techniques (general aspects)</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>prostate cancer</subject><subject>prostate-specific antigen</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Hyperplasia - diagnosis</subject><subject>Prostatic Hyperplasia - physiopathology</subject><subject>Prostatic Neoplasms - diagnosis</subject><subject>reference validation</subject><subject>Reference Values</subject><subject>ROC Curve</subject><subject>Sensitivity and Specificity</subject><subject>Turkey</subject><issn>1434-6621</issn><issn>1437-4331</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkD2P1DAQhiME4j6gpEVuoMueHX8lUJ1WHCAtojloo4kzXnx4nWA7oP0B_G-8H9I1VB6PnhnN-1TVK0ZXTDJ5s15vvqwaSvVKUvakumSC61pwzp4ea1Er1bCL6iqlB0qZlEI_ry6YVkxTri-rv9_BL5iInSKxEfEmTxk8meOUMmSs04zGWWcIhOy2GEiE7CYCiQCxSzDlE8hkCWzxHQloMCWX94dORIsRg0HyG7wb4Ui6UObul_jTpR9knubFH_svqmcWfMKX5_e6-nb34X79qd58_fh5fbupDdc818yKTitsbSfEUMLDCGxolaCjga7BgYJqmezQjsqOsmFGqXZQqLrOCOCI_Lp6e9pb8v0qsXO_c8mg9xBwWlKvqaad1ryA9Qk0RUQqUfo5uh3Efc9of_DeH7z3B-998V741-fFy7DD8ZE-iy7AmzMAyYC3EYJx6ZFrOyk1FYV7f-L-gM8YR9zGZV-K_mFaYihu_n-AkLpjDf8HIKKgMQ</recordid><startdate>20070101</startdate><enddate>20070101</enddate><creator>Mungan, A. Gorkem</creator><creator>Erol, Bulent</creator><creator>Akduman, Bulent</creator><creator>Bozdogan, Gurdal</creator><creator>Kiran, Sibel</creator><creator>Yesilli, Cetin</creator><creator>Mungan, N. Aydin</creator><general>Walter de Gruyter</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20070101</creationdate><title>Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population</title><author>Mungan, A. Gorkem ; Erol, Bulent ; Akduman, Bulent ; Bozdogan, Gurdal ; Kiran, Sibel ; Yesilli, Cetin ; Mungan, N. Aydin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-1f4976e8f944b515ada1b8640dca92eb0a68159efd6fd521c668b6e699c4a3ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adult</topic><topic>age</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Aging - blood</topic><topic>Biological and medical sciences</topic><topic>General aspects</topic><topic>Humans</topic><topic>Investigative techniques, diagnostic techniques (general aspects)</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>prostate cancer</topic><topic>prostate-specific antigen</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Hyperplasia - diagnosis</topic><topic>Prostatic Hyperplasia - physiopathology</topic><topic>Prostatic Neoplasms - diagnosis</topic><topic>reference validation</topic><topic>Reference Values</topic><topic>ROC Curve</topic><topic>Sensitivity and Specificity</topic><topic>Turkey</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Mungan, A. Gorkem</creatorcontrib><creatorcontrib>Erol, Bulent</creatorcontrib><creatorcontrib>Akduman, Bulent</creatorcontrib><creatorcontrib>Bozdogan, Gurdal</creatorcontrib><creatorcontrib>Kiran, Sibel</creatorcontrib><creatorcontrib>Yesilli, Cetin</creatorcontrib><creatorcontrib>Mungan, N. Aydin</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical chemistry and laboratory medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Mungan, A. Gorkem</au><au>Erol, Bulent</au><au>Akduman, Bulent</au><au>Bozdogan, Gurdal</au><au>Kiran, Sibel</au><au>Yesilli, Cetin</au><au>Mungan, N. Aydin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population</atitle><jtitle>Clinical chemistry and laboratory medicine</jtitle><addtitle>Clin Chem Lab Med</addtitle><date>2007-01-01</date><risdate>2007</risdate><volume>45</volume><issue>7</issue><spage>912</spage><epage>916</epage><pages>912-916</pages><issn>1434-6621</issn><eissn>1437-4331</eissn><abstract>: The aim of this study was to evaluate age-related changes in free/total prostate-specific antigen (f/t PSA) ratio, focusing on the avoidance of unnecessary prostate biopsies. : A total of 898 men aged 30–88 years without a history of prostate surgery and disease were enrolled into the study. Serum tPSA, fPSA and f/t PSA ratios were determined for the study population and for different age categories. All males who had suspicious digital rectal examination and tPSA &gt;4 ng/mL underwent transrectal ultrasonography-guided prostate biopsy. Receiver operating characteristic (ROC) curves for each group were generated by plotting the sensitivity vs. 1–specificity for the f/t PSA ratio. The sensitivity and specificity were obtained using different f/t PSA ratio cutoffs for different age groups. : Prostate cancer was detected in 63 patients (7%). Age-specific cutoffs were determined according to likelihood ratios at the levels of 10%, 15% and 15% f/t PSA ratio for ages 50–59, 60–69 and ≥70 years, respectively. However, a single cutoff of 10% is recommended across all age ranges (positive likelihood ratio 2.36). ROC curves demonstrated that the area under the curve (AUC) was significant for all patients with initial PSA of 4–10 ng/mL (AUC 0.703–0.796), except for the ≥70-year age group (AUC 0.549). : The current study showed that the use of f/t PSA ratio in patients with PSA levels of 4–10 ng/mL should enhance the specificity of PSA screening and decrease the number of unnecessary biopsies. f/t PSA levels may show dissimilarities according to age and ethnicity, so further studies are warranted to identify this relationship. Clin Chem Lab Med 2007;45:912–6.</abstract><cop>Berlin</cop><cop>New York, NY</cop><pub>Walter de Gruyter</pub><pmid>17617037</pmid><doi>10.1515/CCLM.2007.501</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1434-6621
ispartof Clinical chemistry and laboratory medicine, 2007-01, Vol.45 (7), p.912-916
issn 1434-6621
1437-4331
language eng
recordid cdi_proquest_miscellaneous_70709773
source MEDLINE; De Gruyter journals
subjects Adult
age
Aged
Aged, 80 and over
Aging - blood
Biological and medical sciences
General aspects
Humans
Investigative techniques, diagnostic techniques (general aspects)
Male
Medical sciences
Middle Aged
prostate cancer
prostate-specific antigen
Prostate-Specific Antigen - blood
Prostatic Hyperplasia - diagnosis
Prostatic Hyperplasia - physiopathology
Prostatic Neoplasms - diagnosis
reference validation
Reference Values
ROC Curve
Sensitivity and Specificity
Turkey
title Values for free/total prostate-specific antigen ratio as a function of age: necessity of reference validation in a Turkish population
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T01%3A20%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Values%20for%20free/total%20prostate-specific%20antigen%20ratio%20as%20a%20function%20of%20age:%20necessity%20of%20reference%20validation%20in%20a%20Turkish%20population&rft.jtitle=Clinical%20chemistry%20and%20laboratory%20medicine&rft.au=Mungan,%20A.%20Gorkem&rft.date=2007-01-01&rft.volume=45&rft.issue=7&rft.spage=912&rft.epage=916&rft.pages=912-916&rft.issn=1434-6621&rft.eissn=1437-4331&rft_id=info:doi/10.1515/CCLM.2007.501&rft_dat=%3Cproquest_cross%3E70709773%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=70709773&rft_id=info:pmid/17617037&rfr_iscdi=true